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Abstract
Background: Breast cancers which demonstrate EGFR protein expression, gene amplification and/or gene
mutations may benefit therapeutically from tyrosine kinase inhibitors. In Western studies, EGFR protein expression
has been demonstrated in 7-36% of breast cancer patients, while gene amplification has been found in around 6%
of cases and mutations were either absent or extremely rare. Studies addressing EGFR protein expression and gene
amplification in Saudi breast cancer patients are extremely scanty and the results reported have been mostly non-
conclusive. Herein we report the prevalence of EGFR protein expression and gene amplification in a cohort of
Saudi breast cancer patients.
Findings: We noticed a remarkably low incidence of EGFR protein expression (1.3%) while analyzing the spectrum
of molecular subtypes of breast cancer in a Saudi population by immunohistochemistry. Also, EGFR gene
amplification could not be demonstrated in any of 231 cases studied using silver enhanced in situ hybridization.
Conclusions: The extremely low incidence of EGFR protein expression and gene amplification in Saudi breast
cancer patients as compared to Western populations is most probably ethnically related as supported by our
previous finding in the same cohort of a spectrum of molecular breast cancer types that is unique to the Saudi
population and in stark contrast with Western and other regionally based studies. Further support to this view is
provided by earlier studies from Saudi Arabia that have similarly shown variability in molecular breast cancer
subtype distribution between Saudi and Caucasian populations as well as a predominance of the high-grade
pathway in breast cancer development in Middle East women. More studies on EGFR in breast cancer are needed
from different regions of Saudi Arabia before our assumption can be confirmed, however.
Findings
Background and research hypothesis
EGFR is a tyrosine kinase receptor in the HER family
which is widely expressed in a number of epithelial
tumors and is believed to play a key role in cell prolif-
eration. It is now well established that non-small-cell
lung cancers which demonstrate EGFR protein expres-
sion, gene amplification and/or gene mutations at exons
18 - 21 show a dramatic therapeutic response to tyro-
sine kinase inhibitors such as gefitinib and erlotinib
[1-3]. Although the same may be true for other cancers
including breast cancer, data regarding the presence or
absence of EGFR abnormalities in tumors other than
lung cancer and the response of such tumors to anti
EGFR therapy are still limited and rather conflicting.
EGFR protein expression as assessed by immunohisto-
chemistry has been demonstrated in 7-36% of breast
cancer patients, while gene amplification as assessed by
CISH or FISH has been found in around 6% of cases
[4-8]. Mutations in exons 18 - 21 of the EGFR gene
investigated by PCR were either absent [1,7] or present
in only rare breast cancer patients [9], such mutations
being much frequent in lung cancer [10]. Differences in
the prevalence of EGFR over-expression reported by dif-
ferent studies have been attributed to probable varia-
tions in techniques and type of antibodies used, criteria
for determining over-expression and inter-observer
variability [7]. * Correspondence: melshawarby46@hotmail.com
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cular subtypes of breast cancer in a Saudi population
[11], we noticed (but have not reported) a remarkably
low incidence of EGFR protein expression in our
patients. Also, EGFR gene amplification could not be
demonstrated in any of 231 cases studied using silver
enhanced in situ hybridization (assessed after the study
was published). In this article we aim to explore whether
this extremely low incidence of protein expression and
gene amplification reflects a truly low prevalence of
EGFR gene abnormalities in the Saudi population which
may be ethnically related or is, alternatively, due to pos-
sible suboptimal sensitivity of the immunohistochemis-
try technique/antibodies or the in situ hybridization
method used.
Patients, methods and results
We have recently published a study that analyzed the
spectrum of molecular subtypes of breast cancer in 231
Saudi patients [11]. The age of the patients ranged
between 25 and 97 years with a mean of 49.5 years (SD
± 11). Representative cancerous tissues obtained from
paraffin blocks of mastectomy and lumpectomy speci-
mens were incorporated into 5 tissue microarray
reception blocks, from which 4 micron thick sections
were cut for immunohistochemical and in situ hybridi-
zation studies. For tru-cut biopsies, conventional paraf-
fin blocks were utilized. The cases were randomly
selected from the archives of our pathology department
based on the availability of representative blocks and
sufficient tissue material to perform the required proce-
dures. An immunohistochemical panel including ER, PR,
HER2, Ck5/6 and EGFR antibodies was used as a surro-
gate for gene expression profiling to classify the 231
breast cancer specimens. Moreover, each class was cor-
related with its Ki-67 proliferation index and p53 gene
over-expression, as revealed by IHC, and also with the
histologic type and grade of the tumor. The histopatho-
logical and molecular charcteristics of breast cancer in
these patients are shown in table 1.
The anti EGFR antibody was used solely as an indica-
tor of the basal molecular subtype (together with CK5/
6) and we have not reported or commented on the pre-
valence of EGFR protein expression among the studied
cohort. A revisit to the study revealed that only three
out of 231 cases were positive for EGFR (1.3%). Positiv-
ity was defined as membrane staining (Figure 1A) and
was scored according to the criteria originally developed
Table 1 Histolopathogical and molecular characteristics of cancer in a cohort of 231 Saudi breast cancer patients
Histologic type LUMA No.(%) LUMB No(%) HER2 No(%) Basal No(%) Hybrid No(%) UC N0(%) Total No(%)
IDC 6 (3.3) 27 (14.8) 29 (15.8) 20 (10.9) 16 (8.7) 85 (46.4) 183 (79.2)
ILC 3 (33.3) 5 (55.6) 0 (0) 0 (0) 0 (0) 1 (11.1) 9 (3.89)
ISC 0 (0) 3 (20.) 7 (46.7) 0 (0) 3 (20) 2 (13.3) 15 (6.49)
other* 0 (0) 2 (8.3) 4 (16.7) 3 (12.5) 4 (16.7) 11(45.8) 24 (10.38)
IDC = Invasive ductal carcinoma-NOS, ILC = Invasive lobular carcinoma, ISC = In situ carcinoma, LUMA = luminal A, LUMB = luminal B, HER2 = human epidermal
growth factor receptor 2, UC = unclassified
*Include medullary carcinoma, mixed ductal and lobular carcinoma, metaplastic carcinoma, apocrine carcinoma and juvenile secretory carcinoma
A B
Figure 1 EGFR protein expression by immunohistochemistry and gene amplification by SISH in a case of metaplastic breast
carcinoma. A) Membrane positivity by immunohistochemistry, × 100 B) No gene amplification (less than 5 gene copies per nucleus) by SISH, ×
400.
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membrane staining of 10% or more of the tumor cells
was considered positive. Cytoplasmic staining alone was
interpreted as negative. We used a primary antibody
manufactured by Dako (clone H11 at a dilution of
1:200). The staining was performed in a Ventana Bench-
mark automated immunostainer according to the manu-
facturer’s instructions (Ventana Medical Systems Inc.,
Tucson, Arizona). All three EGFR positive cases were
negative for ER, PR and HER2 and two were also posi-
tive for CK5/6. We classified the three cases as “basal”
based on Ck5/6 and/or EGFR positivity coupled with
ER, PR and HER2 negativity. Table 2 shows the immu-
nohistochemical findings in the EGFR positive cases
including the Ki67 proliferation index which was high
(70-100%). The patients were aged 35, 61 and 78 years.
All had a high grade (grade III) invasive carcinoma but
only one had an advanced (stage IV) disease (table 3).
Although the number of the EGFR positive breast can-
cer cases is too small to allow for any correlation with
clinical, pathologic or molecular variables, the presence
of two “metaplastic” carcinomas out of three EGFR posi-
tive cases is in keeping with what has already been
reported in the literature that approximately 70-80% of
metaplastic breast carcinomas overexpress EGFR [12].
On the other hand, EGFR gene amplification - assessed
after the study was published using the newly intro-
duced silver enhanced in situ hybridization “SISH” tech-
nique (Ventana Medical Systems Inc., Tucson, Arizona)
- could not be demonstrated in any of the 231 cases.
The SISH detection kit utuilizes an enzyme labeled anti-
body that blocks the bound primary antibody. The com-
plex is then visualized by silver acetate chromagen
which produces a black precipitate. During the ISH pro-
cess, labeled probes are bound to specific DNA or RNA
target sequences in cells or tissues. Visualization of the
bound linker antibody is accomplished through enzyme
catalyzed deposition of silver. Silver ions are reduced by
hydroquinone to metallic silver ions. The substrate for
the enzyme catalyzed deposition of silver is hydrogen
peroxide. The test was performed on 4 micron thick
paraffin sections prepared from TMA and conventional
blocks in a Ventana Benchmark IHC/ISH instrument
(Ventana Medical Systems Inc., Tucson, Arizona) using
an EGFR DNA probe (Ventana Medical Systems Inc.,
Tucson, Arizona) according to the manufacturer’s
instructions. The results were evaluated by light micro-
scopy under a 40× objective. The SISH signals (black)
were counted in at least 20 nuclei (Figure 1B). Gene
amplification was defined as copy number greater than
5/nucleus.
Comment, conclusions and recommendation
The remarkably lower incidence of protein expression
and gene amplification in our breast cancer cases as
compared to that reported in Western studies (table 4)
may reflect a truly low prevalence of EGFR gene
abnormalities in the Saudi population which may be
ethnically related. Alternatively, it may be due to possi-
ble suboptimal sensitivity of the immunohistochemistry
technique/antibodies or the in situ hybridization method
used. However, a much greater likelihood of some eth-
nic variation in EGFR gene abnormalities in breast can-
cer is supported by our previous finding in the same
cohort of a spectrum of molecular breast cancer types
that is unique to our population with luminal tumors
comprising 19.9% and unclassified (penta negative)
tumors 42.9% [11]. This distribution is in stark contrast
with Western and other regionally based studies that
have reported a prevalence of 44.5 - 80.2% for luminal
cases [13-18] and 4.87 - 15.9% for the unclassified cate-
gory [13-17]. Further support to this view is provided by
earlier studies from Saudi Arabia that have similarly
shown variability in molecular breast cancer subtype dis-
tribution between Saudi and Caucasian populations
[19-21] as well as a predominance of the high-grade
pathway in breast cancer development in Middle East
women [19]. There are also other features that distin-
guish breast cancer in Saudi women from what is seen
in Western populations. Breast cancers in Saudi women
are generally locally advanced at the time of diagnosis,
and affect predominantly females between 46-50 years
of age, which is noticeably different from the median of
60-65 years seen in industrialized Western nations
[22,23], where locally advanced disease is much less
common.
Table 2 Immunohistochemical findings and Ki67 index in
EGFR positive breast cancer cases
Case No ER PR HER 2 CK 5/6 EGFR Ki67 index
1 -ve -ve -ve +ve +ve (2+) High (100%)
2 -ve -ve -ve +ve +ve (3+) High (100%)
3 -ve -ve -ve -ve +ve (2+) High (70%)
Table 3 Histologic type in relation to patient age, tumor grade and tumor stage in EGFR positive breast cancer cases
Case No Histologic type Patient age (years) Tumor grade Tumor stage
1 Metaplastic carcinoma 35 III pT2N0M0 (IIA)
2 Invasive ductal carcinoma, NOS 61 III pT2N0M0 (IIA)
3 Metaplastic carcinoma 78 III pTXNXM1 (IV)
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would be to attempt confirming an extremely low preva-
lence of EGFR gene amplification in Saudi patients using
PCR which is a more sensitive method than all in situ
hybridization techniques. Moreover, by PCR, we can
explore mutations at various exons of the EGFR gene,
which may not necessarily be reflected as gene amplifi-
cation or protein expression but are still effective in
determining prognosis and response to anti EGFR ther-
apy. Studies addressing EGFR protein expression and
gene amplification in Saudi breast cancer patients are
extremely scanty and the results reported have been
mostly non-conclusive [19]. More studies in this direc-
tion are encouraged from different regions of Saudi
Arabia.
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Table 4 Prevalence of EGFR protein expression and gene
amplification in present study compared to Western
studies
EGFR protein
expression %
EGFR gene
amplification %
Present study 1.3 0
Harris et al [4] 16 Not done
Tsutsui et al [5] 36 Not done
Walker & Dearing [6] 36 Not done
Bhargava et al [7] 7 6
Press et al [8] 27.9 Not done
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